Background: The COVID-19 pandemic, driven by SARS-CoV-2, necessitated the rapid development and global deployment of vaccines. Despite the high efficacy of vaccines like AstraZeneca and Pfizer-BioNTech in preventing severe COVID-19, concerns about potential side effects, particularly on male fertility, have arisen.
Objective: This study aims to evaluate the impact of COVID-19 vaccination on key sperm parameters (motility, concentration, count, and morphology) and serum interleukin-6 (IL-6) levels in men.
Materials and methods: A cross-sectional study was conducted over six months
(March to August 2022) at the High Institute for Infertility Diagnosis and Assisted Reproductive Technologies in Baghdad, Iraq. The study included 63 participants divided into three groups: AstraZeneca vaccine group (N=24), Pfizer vaccine group (N=19), and an unvaccinated control group (N=20). Participants’ sperm parameters were analyzed following the WHO guidelines, and serum IL-6 levels were measured using ELISA.
Results: No statistically significant differences were found in sperm motility, concentration, total sperm count, or morphology between vaccinated and unvaccinated groups. Specifically, sperm motility was 57.3±8.9% in the vaccinated group versus 56.8±9.2% in the control group (p=0.782). Sperm concentration was 62.5±14.7 M/mL in the vaccinated group compared to 61.9±15.1 M/mL in the control group (p=0.845). Total sperm count was 185.6±43.8 M in the vaccinated group versus 183.2±44.5 M in the control group (p=0.802). Morphologically normal sperm were 4.2±1.1% in the vaccinated group versus 4.1±1.0% in the control group (p=0.659). Serum IL-6 levels showed no significant differences between the groups.
Conclusion: COVID-19 vaccination with either AstraZeneca or Pfizer-BioNTech does not adversely affect sperm parameters or induce significant changes in serum IL-6 levels. These findings support the safety of COVID-19 vaccines concerning male reproductive health, alleviating concerns about potential adverse effects on fertility.
